Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Rhea-AI Summary

Gyre Therapeutics (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company, has announced its participation in the 8th Annual H.C. Wainwright MASH Investor Conference. The company, which focuses on developing treatments for various chronic organ diseases, will be represented by CEO Han Ying, PhD, who will present a company overview on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT).

Investors and interested parties can access the live webcast of the presentation through the Events and Presentations page on Gyre's website. For those unable to attend the live session, a replay of the webcast will be made available following the event.

News Market Reaction – GYRE

-3.75%

-3.75% Session move

In the trading session that priced this news, GYRE declined 3.75%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the 8^th Annual H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT).

The live webcast will be available on the Events and Presentations page of Gyre’s website. A webcast replay will be accessible following the live session.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in MASH is based on the company’s experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

For Investors:
Stephen Jasper
stephen@gilmartinir.com

FAQ

When is Gyre Therapeutics (GYRE) presenting at the H.C. Wainwright MASH Investor Conference?

Gyre Therapeutics (GYRE) is presenting at the H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT).

Who will be presenting for Gyre Therapeutics (GYRE) at the investor conference?

Han Ying, PhD, the Chief Executive Officer of Gyre Therapeutics (GYRE), will be presenting a company overview at the investor conference.

How can investors access Gyre Therapeutics' (GYRE) presentation at the H.C. Wainwright conference?

Investors can access the live webcast of Gyre Therapeutics' (GYRE) presentation through the Events and Presentations page on the company's website. A replay will also be available after the live session.

What is the focus of Gyre Therapeutics' (GYRE) clinical development programs?

Gyre Therapeutics (GYRE) focuses its clinical development programs on a variety of chronic organ diseases.